SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Glenmark spurts on receiving USFDA approval for generic version of Solaraze Gel

15 Sep 2016 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs 898.40, up by 5.70 points or 0.64% from its previous closing of Rs 892.70 on the BSE.

The scrip opened at Rs. 895.00 and has touched a high and low of Rs. 904.00 and Rs. 892.45 respectively. So far 45943 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1074.90 on 06-Oct-2015 and a 52 week low of Rs. 671.50 on 12-Feb-2016.

Last one week high and low of the scrip stood at Rs. 915.00 and Rs. 870.00 respectively. The current market cap of the company is Rs. 25366.92 crore.

The promoters holding in the company stood at 46.48%, while Institutions and Non-Institutions held 42.06% and 11.46% respectively.

Glenmark Pharmaceuticals Inc., USA (Glenmark) has been granted final approval by the United States Food & Drug Administration (USFDA) for Diclofenac Sodium Gel, 3%, the generic version of Solaraze Gel, 3% of Fougera Pharmaceuticals Inc.

The Solaraze Gel, 3% market had achieved annual sales of approximately $297.9 million, according to IMS Health sales data for the twelve month period ending July 2016.

Glenmark’s current portfolio consists of 110 products authorized for distribution in the US marketplace and 61 ANDA’s pending approval with the USFDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

Glenmark Pharma Share Price

2242.15 12.50 (0.56%)
21-Apr-2026 11:07 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.00
Dr. Reddys Lab 1222.65
Cipla 1229.95
Zydus Lifesciences 931.80
Lupin 2323.00
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×